The stock price of Edgewise Therapeutics Inc (NASDAQ: EWTX) has jumped by 8.65 compared to previous close of 25.33. Despite this, the company has seen a gain of 3.61% in its stock price over the last five trading days. seekingalpha.com reported 2024-12-31 that Company achieved positive phase 2 CANYON study results for sevasemten in Becker Muscular Dystrophy, boosting long-term investment potential. Key catalysts include FDA and EMA meetings, GRAND CANYON study recruitment completion, and phase 2 CANYON data publication, all expected to likely enhance shareholder value. The pipeline extends beyond BMD, with sevasemten in phase 2 trials for Duchenne Muscular Dystrophy and EDG-7500 targeting Hypertrophic Cardiomyopathy, offering multiple growth opportunities.
Is It Worth Investing in Edgewise Therapeutics Inc (NASDAQ: EWTX) Right Now?
Moreover, the 36-month beta value for EWTX is 0.21. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EWTX is 62.40M and currently, short sellers hold a 9.84% of that float. On January 15, 2025, EWTX’s average trading volume was 804.74K shares.
EWTX’s Market Performance
EWTX stock saw a decrease of 3.61% in the past week, with a monthly decline of -7.65% and a quarterly a decrease of -13.78%. The volatility ratio for the week is 7.55%, and the volatility levels for the last 30 days are 7.40% for Edgewise Therapeutics Inc (EWTX).. The simple moving average for the past 20 days is -2.23% for EWTX’s stock, with a 18.70% simple moving average for the past 200 days.
Analysts’ Opinion of EWTX
Many brokerage firms have already submitted their reports for EWTX stocks, with Evercore ISI repeating the rating for EWTX by listing it as a “Outperform.” The predicted price for EWTX in the upcoming period, according to Evercore ISI is $45 based on the research report published on November 22, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see EWTX reach a price target of $48. The rating they have provided for EWTX stocks is “Overweight” according to the report published on March 07th, 2024.
EWTX Trading at -10.80% from the 50-Day Moving Average
After a stumble in the market that brought EWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.81% of loss for the given period.
Volatility was left at 7.40%, however, over the last 30 days, the volatility rate increased by 7.55%, as shares sank -2.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.41% lower at present.
During the last 5 trading sessions, EWTX rose by +3.61%, which changed the moving average for the period of 200-days by +53.23% in comparison to the 20-day moving average, which settled at $28.15. In addition, Edgewise Therapeutics Inc saw 3.07% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EWTX starting from Russell Alan J, who sale 100,000 shares at the price of $27.37 back on Dec 30 ’24. After this action, Russell Alan J now owns 14,863 shares of Edgewise Therapeutics Inc, valued at $2,737,470 using the latest closing price.
ALAN J RUSSELL, the Director of Edgewise Therapeutics Inc, proposed sale 100,000 shares at $28.74 during a trade that took place back on Dec 30 ’24, which means that ALAN J RUSSELL is holding shares at $2,874,000 based on the most recent closing price.
Stock Fundamentals for EWTX
Current profitability levels for the company are sitting at:
- -65.34 for the present operating margin
- 0.29 for the gross margin
The net margin for Edgewise Therapeutics Inc stands at -55.19. The total capital return value is set at -0.3. Equity return is now at value -31.90, with -30.22 for asset returns.
Based on Edgewise Therapeutics Inc (EWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -24.53. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -47.36.
Currently, EBITDA for the company is -112.81 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 1139.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 26.35.
Conclusion
To wrap up, the performance of Edgewise Therapeutics Inc (EWTX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
